Cymabay Therapeutics, Inc. (NASDAQ: CBAY) was founded in 1988, formerly known as Metabolex, Inc., headquartered in Newark, California, USA, with 22 full-time employees. It is a biopharmaceutical company focusing on the development and commercialization of professional and orphan drugs .
Cymabay Therapeutics, Inc. (CBAY):
Cymabay Therapeutics products include:
- seladelpar (MBX-8025), a selective agonist of peroxisome proliferator-activated receptor δ, has completed a phase II clinical study for the treatment of primary cholangitis and homozygous familial hypercholesterolemia .
- arhalofenate-Five phase II clinical trials for the treatment of gout have been completed.
- MBX-2982-an oral G protein coupled receptor agonist for the treatment of type II diabetes.
CymaBay Therapeutics Inc. and Kowa Pharmaceuticals America, Inc. signed a license agreement to develop and commercialize arhalofenate in the United States; signed a development and license agreement with Janssen Pharmaceuticals, Inc. to develop and discover therapeutic II An undisclosed metabolic disease targeted agonist for type 2 diabetes and other diseases; signed a license and development agreement with DiaTex, Inc. to develop and commercialize haofenate, its enantiomers, derivatives and analogs Therapeutic products to treat diseases.